

MORE ENERGY, WHERE NEEDED



 **indena**[®]
INDUSTRIA
DERIVATI
NATURALI

NUTRACEUTICAL

UBIQSOME[®]

COQ10 INDENA PHYTOSOME[™]

ubi**some**[™]

Please note this documentation is available for various countries all over the world and hence it may contain statements or product classification not applicable to your country. The claims made are in reference to ingredients only, hence they do not refer to finished products and they may not comply with Regulation EC n. 1924/2006. The marketer of any finished product containing any ingredient is responsible for assuring that the destination of the product and the claims made for the finished product are lawful and comply with all applicable laws and regulations of the country or countries in which the product is to be sold.

WHAT IS UBIQSOME®?

UBIQSOME® is the **optimized delivery form of coenzyme Q10**, formulated with the Indena Phytosome™ proprietary technology.

Coenzyme Q10 (CoQ10) - also known as ubiquinone or ubidecarenone - is an **essential endogenous cofactor for the electrontransport chain in the mitochondria**, and also exerts a fundamental antioxidant activity in the cells.

As the only known lipid antioxidant that can be synthesized by animal cells,¹ it exerts a **crucial role in the maintenance of cells bioenergetics** promoting therefore: **sport activities, healthy ageing, heart & cardiovascular health, brain health** and many other activities involving energetic expenditure.

Since the oral bioavailability of CoQ10 is quite poor, due to its high molecular weight and very low aqueous solubility, it has been **formulated with Indena Phytosome™ technology in order to optimize the bioabsorption of this important cofactor.**⁴

SPECIFICATIONS

UBIQSOME® is standardized to contain: **18-22% of coenzyme Q10** by HPLC.

RECOMMENDED USE AND DOSE

UBIQSOME® is a **brown yellow powder** for use in a **variety of supplement formulations**.

Suggested dose: **up to 500 mg/day**.

TRADEMARKS

QUERCEFIT® is a trademark of Indena S.p.A. and its logo and usage guidelines are available from Indena.

WHAT MAKES UBIQSOME® UNIQUE?

UBIQSOME® emerges as the **real game-changer in the field of CoQ10-based ingredients**: thanks to its proprietary **Indena Phytosome™** technology and proven via various scientific evidences, it **delivers coenzyme Q10 to the intended target muscle cells**.

Improvement of coenzyme Q10 in muscle cells after UBIQSOME® supplementation was uniquely proven on healthy, aging runners, and further confirmed in ex-vivo and preclinical investigations.²⁻⁴

UBIQSOME® also **ensures optimal CoQ10 plasma levels even after just one supplementation**, and shows an evident **dose-dependent trend** after a mere 2 weeks of intake.⁵

Antioxidant power of CoQ10 enhanced in UBIQSOME® allows to support muscle function in several discomforts, including physical and sport distress, also favouring muscle health in case of long-term treatments (e.g. statins and GLP-1 agonists).

A human study showed **UBIQSOME®** has **beneficial effects on elderly people with statin-related asthenia**. What is the mechanism behind this evidence?

Statin act by blocking the molecular pathway that leads to the synthesis of cholesterol, and in parallel also to the formation of CoQ10.⁶

Clinical evidence in healthy young adults shows that **UBIQSOME® supplementation enhances endothelial function both acutely and over time**, being endothelial function a key early indicator of cardiovascular health.⁷

UBIQSOME® is furthermore the **valuable ally to nurture skin health from within**: human evidence show its capacity to **increase CoQ10 content in dermal fibroblasts after oral intake**.³

References

¹ Laredj, L.N. et al., *Biochimie* 2014, 100, 78-87

² Drobnic F. et al., *J Food Sci Nutr Res* 3 (4):262-275 (2020).

³ Marcheggiani F. et al., *Antioxidants* 12:4:964 (2023).

⁴ Rizzardi N. et al., *Antioxidants* 0:6: 927 (2021).

⁵ Petrangolini G. et al., *Curr Drug Deliv* 16(8):759-767 (2019).

⁶ Fogacci F. et al., *Journal of Clinical Medicine* 13:13:3741 (2024).

⁷ Cicero AFG. et al., *Biofactors. Sep*;48(5):1160-1165 (2022).

indena.com

